Search clinical trials for: Glucagon-like peptide-1 receptor agonists (GLP 1 RA)

Total 1381 results

University of Missouri-Columbia
American Society for Metabolic and Bariatric Surgery

Recruiting

Impact GLP-1 Agonists Following Bariatric

Hypertension | Diabetes Mellitus | Metabolic Syndrome | Morbid Obesity | Obstructive Sleep Apnea of Adult

United States
Herlev Hospital
University of Copenhagen; The Danish Medical Research Council; The Danish Diabetes...

Completed

GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia

Type 2 Diabetes Mellitus

Denmark
University of Chicago

Completed

Incretin Regulation of Insulin Secretion in Monogenic Diabetes

Monogenic Diabetes

United States
Uppsala University
Karolinska Institutet; University of Copenhagen

Completed

GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose (GIP-GLP-gas)

Physiology | Gastroenterology | Endocrinology

Sweden
Hvidovre University Hospital

Completed

Incretin Hormone Antagonism After Bariatric Surgery (INCA-BAR)

Bariatric Surgery

Denmark
Bayer

Active, not recruiting

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice (FINEGUST)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

Japan, Spain, Netherlands, United Kingdom, Denmark, United States
University Hospital, Gentofte, Copenhagen

Completed

GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake (GASOLIN)

Obesity | Type 2 Diabetes | Adiposity

Denmark
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DM

Type 2 Diabetes Mellitus

China
University of Maryland, Baltimore

Active, not recruiting

GLP-1 and Hypoglycemia

Type 2 Diabetes Mellitus

United States
Johns Hopkins University

Terminated

The Effect of Surgically Induced Weight Loss on Endocrine Function, Cardiovascular Function and Body Composition

Bariatric Surgery

United States
University of Copenhagen
Hvidovre University Hospital

Completed

Gut Hormones and Bone Remodeling in Humans (KS-2) (KS-2)

Healthy

Denmark
University of Copenhagen
Hvidovre University Hospital

Completed

Effects of Gut Peptides on Bone Remodeling (KS-3)

Healthy

Denmark
Uppsala University
Karolinska Institutet

Completed

GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans (GLPMOT)

Functional Gastrointestinal Disorders

Sweden
Christina Kruuse

Recruiting

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke (EGRABIS1)

Ischemic Stroke

Denmark
Johns Hopkins University
Society of Critical Care Medicine

Terminated

The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients

Hypoglycemia | Critically Ill

United States
University Hospital, Gentofte, Copenhagen

Completed

The Effect of GLP-1 on the Inhibition of Glucagon Secretion

Type 1 Diabetes | Type 2 Diabetes

Denmark
University of Copenhagen
Hvidovre University Hospital

Recruiting

Gut Peptides and Bone Remodeling in Individuals With Spinal Cord Injury

Spinal Cord Injuries

Denmark
University of Aarhus

Completed

GLP-1 Infusion and Long-Time Fasting

Type 2 Diabetes

Denmark
Mikkel Christensen

Completed

Glucose-Dependent Insulinotropic Polypeptide - Effects on Markers of Bone Turnover in Patients With Type 1 Diabetes

Type 1 Diabetes Mellitus
Ali Aminian

Not yet recruiting

Fibrosis Lessens After Metabolic Surgery (FLAMES)

Obesity | Liver Fibrosis | Non-Alcoholic Fatty Liver Disease | Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) | Metabolic Dysfunction-Associated Steatohepatitis (MASH)

United States, Sweden, Ireland, Finland, United Kingdom, Spain, Switzerland, Brazil, Canada, Italy, Kuwait, India, Mexico
Christina Kruuse

Completed

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers (EGRABINS1)

Stroke

Denmark
Mayo Clinic
National Center for Research Resources (NCRR); Rose Pharma A/S

Completed

Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients

Irritable Bowel Syndrome Constipation Predominant

United States
University Hospital, Gentofte, Copenhagen

Completed

Oxyntomodulin, Mechanisms of Action in Relation to Appetite, Food Intake, Gastric Emptying and Energy Expenditure.

Obesity | Incretin Action

Denmark
Oslo University Hospital

Completed

GLP-1 Effects on Insulin and Glucagon in PTDM

Post-transplant Diabetes Mellitus

Norway
University of Aarhus

Completed

Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET

Healthy

Denmark
Indiana University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Modulation of Human Myocardial Metabolism by GLP-1 Dose Response

Healthy | Type 2 Diabetes Mellitus

United States
Second Xiangya Hospital of Central South University
Guangdong Provincial People's Hospital; The First Affiliated Hospital of Henan... and other collaborators

Recruiting

The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.

Diabetes Mellitus, Type 2 | Overweight or Obesity

China
University of Copenhagen
Copenhagen University Hospital, Hvidovre

Recruiting

Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.

Obesity

Denmark
Karl Neff
University College Dublin

Completed

The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease

Diabetic Kidney Disease

Ireland
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute

Recruiting

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes (PRECIDENTD)

Type2Diabetes | ASCVD

United States
Western University, Canada
Unity Health Toronto; Lawson Health Research Institute; Queen Elizabeth II Health...

Not yet recruiting

Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2

Obesity | Chronic Kidney Disease

Canada
University Health Network, Toronto

Completed

Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like Peptide 2

Dyslipidemia

Canada
Rigshospitalet, Denmark
Department of Cardiovascular and Renal Research, University of Southern Denmark

Completed

Acute Effects of GLP-1 on Renal Hemodynamics (GLP1RRBF)

The GLP-1-mediated Gut-kidney Axis

Denmark
University of Copenhagen
Hvidovre University Hospital

Completed

Investigation of GLP-2 Mechanism of Action (GA-8)

Healthy

Denmark
Ludwig-Maximilians - University of Munich
German Research Foundation; Merck Sharp & Dohme LLC

Completed

Exendin(9-39)Amide as a Glucagon-like Peptide-1 (GLP-1) Receptor Antagonist in Humans

Hyperglycemia

Germany
Novo Nordisk A/S

Active, not recruiting

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

Obesity | Diabetes Mellitus, Type 2

United States, Canada, Hungary, Portugal, Slovakia, South Africa, Poland, Bulgaria
Novo Nordisk A/S

Active, not recruiting

A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) (STEP UP)

Obesity

United States, Czechia, Germany, Canada, Hungary, Portugal, Norway, South Africa, Poland, Greece, Bulgaria, Slovakia
Papworth Hospital NHS Foundation Trust

Unknown

GLP-1 Loading During Elective Percutaneous Coronary Intervention (GOLD-PCI)

Myocardial Infarction | Angina Pectoris | Coronary Heart Disease | Reperfusion Injury

United Kingdom
Johns Hopkins University

Terminated

Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery (GLP-1 CABG)

CABG

United States
University of Florida
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Effects of Exenatide on Motor Function and the Brain

Parkinson's Disease

United States
Novo Nordisk A/S

Completed

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range (OASIS 4)

Obesity | Overweight

Germany, United States, Canada, Poland
Novo Nordisk A/S

Not yet recruiting

Remote Study Collecting Blood Glucose Values and Activity Data in Patients With Type 2 Diabetes on Different Treatments

Diabetes Mellitus, Type 2
Cambridge University Hospitals NHS Foundation Trust

Completed

Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers (COCOA)

Cardiovascular Diseases

United Kingdom
AstraZeneca

Completed

Clinical Outcomes of Exenatide Versus Basal Insulin

Type 2 Diabetes

United Kingdom
Eli Lilly and Company
Jaeb Center for Health Research; Locemia Solutions ULC

Completed

Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
University Hospital, Gentofte, Copenhagen
Danish Heart Foundation

Completed

Vasodilatory and Metabolic Effects of Glucagon-like Peptide-1 in Periphery Circulation in Patients With and Without Type 2 Diabetes Mellitus

Type 2 Diabetes | Blood Flow | Human Physiology | Glucagon-like Peptide-1 | Blod Pressure

Denmark
Novo Nordisk A/S

Active, not recruiting

DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy (DOORS)

Diabetes Mellitus, Type 2

Italy
Novo Nordisk A/S

Completed

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III

Healthy Participants

Canada
Novo Nordisk A/S

Completed

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice

Diabetes Mellitus, Type 2

Mexico
Novo Nordisk A/S

Enrolling by invitation

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice (PIONEER REAL)

Diabetes Mellitus, Type 2

Finland, France

Search clinical trials for: Glucagon-like peptide-1 receptor agonists (GLP 1 RA)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations